Tag: Mahima Datla
CDSCO nod to Biological E’s pneumonia vaccine for infants
BE’s PCV14 is comparable in terms of serotype coverage for infants to the two pneumococcal conjugate vaccines Prevnar13 and Merck’s VAXNEUVANCE, which are currently approved globally
BioAsia 2022: India’s biotech sector stakeholders discuss learnings from pandemic
Normally a vaccine development process takes 6-8 years for research and trials, but path-breaking work has been done in India
Biological E unveils its Typhoid Conjugate Vaccine, manufacturing plant at Genome...
Biological E has invested Rs 300 Crore to build this Plant that will produce the Typhoid Conjugate Vaccine to protect children against typhoid fever, also generating employment for about 1000 people................